Zacks Research Upgrades CAMP4 Therapeutics (NASDAQ:CAMP) to “Hold”

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other analysts also recently issued reports about the company. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research note on Friday. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.56.

CAMP4 Therapeutics Stock Performance

NASDAQ CAMP opened at $4.90 on Monday. The firm’s fifty day moving average is $4.10 and its two-hundred day moving average is $4.32. CAMP4 Therapeutics has a one year low of $1.41 and a one year high of $7.75. The firm has a market cap of $307.48 million, a PE ratio of -2.11 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The business had revenue of $1.78 million for the quarter. Research analysts predict that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Buying and Selling

In other CAMP4 Therapeutics news, Director Richard A. Young acquired 16,378 shares of the stock in a transaction on Monday, August 3rd. The shares were bought at an average price of $1.65 per share, with a total value of $27,023.70. Following the acquisition, the director owned 186,388 shares of the company’s stock, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 36,031 shares of company stock valued at $59,451 in the last three months. 21.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Large investors have recently modified their holdings of the business. Bridgeway Capital Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new position in CAMP4 Therapeutics during the fourth quarter worth $61,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics during the fourth quarter worth $70,000. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the second quarter worth $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in CAMP4 Therapeutics in the fourth quarter worth $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.